遺伝性がん検査の市場規模、シェア、動向分析レポート：がん別、技術別、検査タイプ別、最終用途別、地域別、セグメント予測、2025年～2030年

遺伝性がん検査市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界の遺伝性がん検査市場規模は2030年までに94億5,290万米ドルに達すると予測され、2025～2030年のCAGRは12.9%で成長すると予測されています。

同市場は、政府支援やヘルスケア資金、消費者直接（DTC）遺伝子検査プラットフォームの成長により、加速しています。遺伝性がんは全体の10％を占め、残りの90％は散発性がんです。このような遺伝性がんの需要増に対応する必要性が生じているが、これはヘルスケア需要を満たすために政府のイニシアティブや資金提供によって可能になる可能性があります。がん予防と遺伝子研究を目的とした政府のイニシアチブと資金提供は、遺伝性がん検査市場を大きく牽引しています。

多くの国が、がんリスク評価プログラムの一環として遺伝子検査を推進する施策を導入しており、検査費用に対する財政的支援を提供していることが多いです。例えば、全米総合がんネットワーク（NCCN）は2025年1月、遺伝性と家族性がんリスクに関する最新の推奨事項を個人に提供することを目的とした新しいリソースを発表しました。このガイドラインは、遺伝性乳がん、卵巣がん、膵臓がん、前立腺がんに焦点を当てたもので、アプリからも入手できます。本ガイドラインは、がんのリスクを高める可能性のある遺伝性遺伝子変異の評価と検査方法について、明確でわかりやすいガイダンスを提供しています。情報はわかりやすく、理解しやすい方法で提供されています。

遺伝性がん検査に関する規制上の承認は、がんリスクの評価に使用される遺伝子検査が正確性、安全性、信頼性に関する厳格な基準を満たしていることを保証するものです。FDAはこれらの検査を医療機器として分類しており、市場使用の承認を受ける前に徹底的な評価を受けなければならないです。米国食品医薬品局（FDA）は2023年9月、複数タイプのがんに対する遺伝的素因を評価するために設計されたDNA検査について、史上初の販売承認を与えました。この画期的な承認により、乳がん、卵巣がん、大腸がんなど、複数のがんのリスク上昇に関連する複数の変異遺伝子に次世代シーケンス（NGS）を通じてアクセスし、感度、スピード、精度の高い知見を得ることができます。これらの遺伝性変異を同定することにより、この検査は、早期発見、予防措置、個人に合わせた治療計画の指針となる貴重な情報を個人に記載しています。今回の承認は、遺伝子検査とがん予防のセグメントにおける重要なマイルストーンであり、個人が健康管理に向けて積極的な手段を講じることができるようにするものです。

ヘルスケアに革命をもたらす遺伝子検査の可能性を認識した政府は、公衆衛生のインフラに遺伝子サービスを統合することを目的としたいくつかのイニシアチブを開始しました。ジョージタウン大学ロンバルディ総合がんセンターとニュージャージー州ラトガースがんラボの研究者に320万米ドルの助成金を授与した国立がんラボは、重要な一歩を踏み出しました。この助成金は、遺伝性がん検査に関する国のガイドラインを満たす黒人がん患者428人を無作為化比較検査に登録する5年間の研究を支援するもので、遺伝子教育への参加、検査受診、インフォームドデシジョン、心理社会的転帰に対するこれらの介入の影響を評価します。遺伝学的検査に対する障壁に対処し、地域社会の意見を取り入れることで、この調査は検診へのアクセスを改善し、がんの医療的管理を改善し、最終的にはがん医療における健康の公平性を推進することを目的としています。

同市場では、Myriad Genetics, Inc.、Bio-Rad Laboratories、F. HOFFMANN-LA ROCHE LTD、Illumina, Inc.などの主要参入企業の活動が確認されています。これらの参入企業は、世界の顧客のニーズを満たすために、USFDAからの製品承認を求めて積極的に取り組んでいます。例えば、2024年6月、Myriad Genetics, Inc.は進行中のイノベーションを発表した：MyChoice CDx HRDとBRACAnalysis CDx Germline Companion Diagnostic Testsは、研究協力を通じて製品ポートフォリオを強化します。さらに、Myriadは、様々ながんにおけるMRDの可能性を調査するため、複数の共同研究を開始しました。さらに、がんの精密医療オンラインスクリーニングツールの開発により、転帰を改善するための患者教育が可能になります。例えば、2025年1月、Myriad Genetics, Inc.は、オンラインスクリーニングツールと遺伝学的教育を併用した場合、患者が遺伝性がん検査を完了する可能性が高くなることを示す研究を発表しました。このアプローチは、がんリスク評価のための遺伝子検査への参加と関心を高める上で、デジタルツールと教育が重要であることを強調しています。

このように、遺伝子検査における技術的進歩、政府のイニシアティブと資金援助の拡大、規制当局の承認促進が、早期発見と疾病予防のための市場成長を後押ししています。

遺伝性がん検査市場レポートハイライト

• がん別では、乳がんは2024年に12.45%の最大の収益シェアを占めました。遺伝性乳がん検査市場は、次世代シーケンサー（NGS）と人工知能（AI）の進歩により、包括的なリスク評価が可能になり、拡大しています。認知度の向上、政府の取り組み、保険適用範囲の拡大が採用をさらに後押ししています。これらの技術革新は早期発見と個別化予防戦略を促進し、患者の転帰を向上させています。
• 技術別では、分子検査が市場を独占し、2024年には56.36%の最大シェアを占めました。遺伝性がん検査市場における分子検査セグメントは、がん有病率の上昇、次世代と迅速遺伝子分析の進歩により拡大しています。これらの技術は診断精度を高め、個別化治療戦略を促進します。さらに、認知度の向上と保険適用が採用を促進しています。
• 検査タイプ別に見ると、2024年には予測遺伝子検査が遺伝性がん検査市場の支配的なセグメントとして浮上し、66.49％のシェアを獲得しました。遺伝性疾患の有病率の増加と予防ヘルスケア重視の高まりが、予測遺伝子検査の採用をさらに後押ししています。
• 最終用途別では、病院が2024年に55.11%の最大シェアを占め、他のセグメントの中で最も急成長しています。病院は研究大学と協力してこの市場の成長を後押ししています。
• 北米は、多数の大手市場参入企業の存在、次世代シークエンシング（NGS）の進歩、遺伝リスクに対する意識の高まり、保険適用範囲の拡大などにより、世界市場を独占しています。
• アジア太平洋のは、2025～2030年にかけてCAGR 14.3%で最速の成長を遂げると予測されます。これは、革新的な技術を持つ主要企業による事業拡大と診断研究能力の加速によるものです。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 遺伝性がん検査市場の変数、動向、範囲

• 市場系統の展望
  • 親市場の展望
  • 関連/補助的な市場展望
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• 遺伝性がん検査市場分析ツール
  • 産業分析-ポーターのファイブフォース分析
  • PESTEL分析

第4章 遺伝性がん検査市場：がん別、推定・動向分析

• セグメントダッシュボード
• 遺伝性がん検査市場：がん変動分析
• 遺伝性がん検査市場規模と動向分析（がん別、2018～2030年）
• 2018～2030年の市場規模と予測と動向分析
• 肺がん
• 乳がん
• 大腸がん
• 子宮頸がん
• 卵巣がん
• 前立腺がん
• 胃がん
• 黒色腫
• 肉腫
• 子宮がん
• 膵臓がん
• その他

第5章 遺伝性がん検査市場：技術別、推定・動向分析

• 技術市場シェア、2024年と2030年
• セグメントダッシュボード
• 技術展望による世界の遺伝性がん検査市場
• 2018～2030年の市場規模と予測と動向分析
• 細胞遺伝学的
• 生化学的
• 分子検査

第6章 検査タイプ市場：検査タイプ別、推定・動向分析

• 検査タイプ市場シェア、2024年と2030年
• セグメントダッシュボード
• 検査タイプ展望による世界の遺伝性がん検査市場
• 2018～2030年の市場規模と予測と動向分析
• 予測検査
• 診断検査

第7章 最終用途市場：最終用途別、推定・動向分析

• 最終用途市場シェア、2024年と2030年
• セグメントダッシュボード
• 最終用途展望による世界の遺伝性がん検査市場
• 2018～2030年の市場規模と予測と動向分析
• 診断センター
• 病院
• クリニック

第8章 遺伝性がん検査市場：地域別、推定・動向分析

• 地域別市場シェア分析、2024年と2030年
• 地域別市場ダッシュボード
• 世界地域市場のスナップショット
• 市場規模、予測動向分析、2018～2030年
• 北米
  • 北米： SWOT分析
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 欧州： SWOT分析
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • スウェーデン
  • デンマーク
• アジア太平洋
  • アジア太平洋： SWOT分析
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ラテンアメリカ： SWOT分析
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 中東・アフリカ：SWOT分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第9章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 企業/競合の分類
• ベンダー情勢
  • 主要販売代理店とチャネルパートナー一覧
  • 主要企業の市場シェア分析、2024年
  • Myriad Genetics, Inc.
  • Invitae Corporation
  • Bio-Rad Laboratories
  • CSL Ltd
  • Qiagen NV
  • Danaher Corporation
  • Thermo Fisher Scientific
  • Abbott Laboratories
  • EUROFINS SCIENTIFIC
  • F. HOFFMANN-LA ROCHE LTD
  • Illumina, Inc.

List of Tables

• Table 1 List of abbreviations
• Table 2 North America Hereditary cancer testing market, by region, 2018 - 2030 (USD Million)
• Table 3 North America Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
• Table 4 North America Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
• Table 5 North America Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
• Table 6 North America Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
• Table 7 U.S Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
• Table 8 U.S Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
• Table 9 U.S Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
• Table 10 U.S Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
• Table 11 Canada Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
• Table 12 Canada Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
• Table 13 Canada Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
• Table 14 Canada Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
• Table 15 Mexico Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
• Table 16 Mexico Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
• Table 17 Mexico Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
• Table 18 Mexico Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
• Table 19 Europe Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
• Table 20 Europe Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
• Table 21 Europe Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
• Table 22 Europe Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
• Table 23 UK Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
• Table 24 UK Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
• Table 25 UK Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
• Table 26 UK Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
• Table 27 Germany Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
• Table 28 Germany Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
• Table 29 Germany Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
• Table 30 Germany Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
• Table 31 France Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
• Table 32 France Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
• Table 33 France Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
• Table 34 France Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
• Table 35 Italy Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
• Table 36 Italy Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
• Table 37 Italy Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
• Table 38 Italy Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
• Table 39 Spain Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
• Table 40 Spain Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
• Table 41 Spain Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
• Table 42 Spain Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
• Table 43 Denmark Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
• Table 44 Denmark Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
• Table 45 Denmark Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
• Table 46 Denmark Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
• Table 47 Sweden Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
• Table 48 Sweden Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
• Table 49 Sweden Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
• Table 50 Sweden Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
• Table 51 Norway Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
• Table 52 Norway Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
• Table 53 Norway Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
• Table 54 Norway Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
• Table 55 Asia Pacific Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
• Table 56 Asia Pacific Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
• Table 57 Asia Pacific Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
• Table 58 Asia Pacific Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
• Table 59 Japan Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
• Table 60 Japan Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
• Table 61 Japan Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
• Table 62 Japan Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
• Table 63 China Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
• Table 64 China Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
• Table 65 China Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
• Table 66 China Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
• Table 67 India Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
• Table 68 India Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
• Table 69 India Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
• Table 70 India Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
• Table 71 Australia Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
• Table 72 Australia Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
• Table 73 Australia Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
• Table 74 Australia Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
• Table 75 South Korea Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
• Table 76 South Korea Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
• Table 77 South Korea Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
• Table 78 South Korea Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
• Table 79 Thailand Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
• Table 80 Thailand Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
• Table 81 Thailand Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
• Table 82 Thailand Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
• Table 83 Latin America Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
• Table 84 Latin America Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
• Table 85 Latin America Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
• Table 86 Latin America Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
• Table 87 Brazil Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
• Table 88 Brazil Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
• Table 89 Brazil Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
• Table 90 Brazil Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
• Table 91 Argentina Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
• Table 92 Argentina Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
• Table 93 Argentina Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
• Table 94 Argentina Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
• Table 95 MEA Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
• Table 96 MEA Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
• Table 97 MEA Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
• Table 98 MEA Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
• Table 99 South Africa Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
• Table 100 South Africa Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
• Table 101 South Africa Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
• Table 102 South Africa Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
• Table 103 Saudi Arabia Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
• Table 104 Saudi Arabia Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
• Table 105 Saudi Arabia Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
• Table 106 Saudi Arabia Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
• Table 107 UAE Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
• Table 108 UAE Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
• Table 109 UAE Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
• Table 110 UAE Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
• Table 111 Kuwait Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
• Table 112 Kuwait Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
• Table 113 Kuwait Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
• Table 114 Kuwait Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Primary interviews in North America
• Fig. 5 Primary interviews in Europe
• Fig. 6 Primary interviews in APAC
• Fig. 7 Primary interviews in Latin America
• Fig. 8 Primary interviews in MEA
• Fig. 9 Market research approaches
• Fig. 10 Value-chain-based sizing & forecasting
• Fig. 11 QFD modeling for market share assessment
• Fig. 12 Market formulation & validation
• Fig. 13 Hereditary cancer testing market: market outlook
• Fig. 14 Hereditary cancer testing competitive insights
• Fig. 15 Parent market outlook
• Fig. 16 Related/ancillary market outlook
• Fig. 17 Penetration and growth prospect mapping
• Fig. 18 Industry value chain analysis
• Fig. 19 Hereditary cancer testing market driver impact
• Fig. 20 Hereditary cancer testing market restraint impact
• Fig. 21 Hereditary cancer testing market strategic initiatives analysis
• Fig. 22 Hereditary cancer testing market: Cancer movement analysis
• Fig. 23 Hereditary cancer testing market: Cancer outlook and key takeaways
• Fig. 24 Hereditary cancer Testing market estimates and forecast, 2018 - 2030
• Fig. 25 Hereditary cancer testing Market: Technology movement analysis
• Fig. 26 Hereditary cancer testing market: Technology outlook and key takeaways
• Fig. 27 Cytogenetic market estimates and forecasts, 2018 - 2030
• Fig. 28 Biochemical market estimates and forecasts,2018 - 2030
• Fig. 29 Molecular Testing market estimates and forecasts,2018 - 2030
• Fig. 30 Hereditary cancer testing Market: Test Type movement analysis
• Fig. 31 Hereditary cancer testing Market: Test Type outlook and key takeaways
• Fig. 32 Predictive Testing market estimates and forecasts, 2018 - 2030
• Fig. 33 Diagnostic Testing market estimates and forecasts, 2018 - 2030
• Fig. 34 Hereditary cancer testing Market: End Use movement analysis
• Fig. 35 Hereditary cancer testing market: End Use outlook and key takeaways
• Fig. 36 Diagnostic Centers market estimates and forecasts, 2018 - 2030
• Fig. 37 Hospitals market estimates and forecasts, 2018 - 2030
• Fig. 38 Clinics market estimates and forecasts, 2018 - 2030
• Fig. 39 Global Hereditary cancer testing market: Regional movement analysis
• Fig. 40 Global Hereditary cancer testing market: Regional outlook and key takeaways
• Fig. 41 Global Hereditary cancer testing market share and leading players
• Fig. 42 North America market share and leading players
• Fig. 43 Europe market share and leading players
• Fig. 44 Asia Pacific market share and leading players
• Fig. 45 Latin America market share and leading players
• Fig. 46 Middle East & Africa market share and leading players
• Fig. 47 North America, by country
• Fig. 48 North America
• Fig. 49 North America market estimates and forecasts, 2018 - 2030
• Fig. 50 U.S.
• Fig. 51 U.S. market estimates and forecasts, 2018 - 2030
• Fig. 52 Canada
• Fig. 53 Canada market estimates and forecasts, 2018 - 2030
• Fig. 54 Mexico
• Fig. 55 Mexico market estimates and forecasts, 2018 - 2030
• Fig. 56 Europe
• Fig. 57 Europe market estimates and forecasts, 2018 - 2030
• Fig. 58 UK
• Fig. 59 UK market estimates and forecasts, 2018 - 2030
• Fig. 60 Germany
• Fig. 61 Germany market estimates and forecasts, 2018 - 2030
• Fig. 62 France
• Fig. 63 France market estimates and forecasts, 2018 - 2030
• Fig. 64 Italy
• Fig. 65 Italy market estimates and forecasts, 2018 - 2030
• Fig. 66 Spain
• Fig. 67 Spain market estimates and forecasts, 2018 - 2030
• Fig. 68 Denmark
• Fig. 69 Denmark market estimates and forecasts, 2018 - 2030
• Fig. 70 Sweden
• Fig. 71 Sweden market estimates and forecasts, 2018 - 2030
• Fig. 72 Norway
• Fig. 73 Norway market estimates and forecasts, 2018 - 2030
• Fig. 74 Asia Pacific
• Fig. 75 Asia Pacific market estimates and forecasts, 2018 - 2030
• Fig. 76 China
• Fig. 77 China market estimates and forecasts, 2018 - 2030
• Fig. 78 Japan
• Fig. 79 Japan market estimates and forecasts, 2018 - 2030
• Fig. 80 India
• Fig. 81 India market estimates and forecasts, 2018 - 2030
• Fig. 82 Thailand
• Fig. 83 Thailand market estimates and forecasts, 2018 - 2030
• Fig. 84 South Korea
• Fig. 85 South Korea market estimates and forecasts, 2018 - 2030
• Fig. 86 Australia
• Fig. 87 Australia market estimates and forecasts, 2018 - 2030
• Fig. 88 Latin America
• Fig. 89 Latin America market estimates and forecasts, 2018 - 2030
• Fig. 90 Brazil
• Fig. 91 Brazil market estimates and forecasts, 2018 - 2030
• Fig. 92 Argentina
• Fig. 93 Argentina market estimates and forecasts, 2018 - 2030
• Fig. 94 Middle East and Africa
• Fig. 95 Middle East and Africa market estimates and forecasts, 2018 - 2030
• Fig. 96 South Africa
• Fig. 97 South Africa market estimates and forecasts, 2018 - 2030
• Fig. 98 Saudi Arabia
• Fig. 99 Saudi Arabia market estimates and forecasts, 2018 - 2030
• Fig. 100 UAE
• Fig. 101 UAE market estimates and forecasts, 2018 - 2030
• Fig. 102 Kuwait
• Fig. 103 Kuwait market estimates and forecasts, 2018 - 2030
• Fig. 104 Market share of key market players - Hereditary cancer testing market

Hereditary Cancer Testing Market Growth & Trends:

The global hereditary cancer testing market size is expected to reach of USD 9,452.9 million by 2030, and is projected to grow at a CAGR of 12.9% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is accelerating, due to government support and healthcare funding and growth of direct-to-consumer (DTC) genetic testing platforms. Hereditary cancer accounts overall to 10% and remaining 90% is sporadic cancer. There arises a need to address this growing demand of hereditary cancer which may be possible by government initiatives and funding to meet the healthcare demand. Government initiatives and funding aim at cancer prevention and genetic research significantly drive the hereditary cancer testing market.

Many countries have introduced policies that promote genetic testing as part of cancer risk assessment programs, often providing financial support for testing costs. For example, the National Comprehensive Cancer Network (NCCN), in January 2025, released a new resource designed to provide individuals with the most up-to-date recommendations on hereditary and familial cancer risks. These guidelines focus on hereditary breast, ovarian, pancreatic and prostate cancer which is available also through and app. It offers clear, easy-to-understand guidance on how to assess and test for inherited genetic mutations that may increase the risk of cancer. The information is available in a straightforward and accessible way for better comprehension.

Regulatory approvals for hereditary cancer testing ensures that genetic tests used to assess cancer risk meet rigorous standards for accuracy, safety, and reliability. The FDA classifies these tests as medical devices, and they must undergo thorough evaluation before receiving approval for market use. U.S. Food and Drug Administration (FDA) in September 2023, granted its first-ever marketing authorization for a DNA test designed to assess the genetic predisposition to multiple types of cancer. This groundbreaking approval can access multiple variant genes through next generation sequencing (NGS) which are linked to an increased risk of several cancers, including breast, ovarian, and colorectal cancers to provide insights with sensitivity, speed and accuracy. By identifying these inherited genetic mutations, the test provides individuals with valuable information to guide early detection, preventive measures, and personalized treatment plans. This approval marks a significant milestone in the field of genetic testing and cancer prevention, empowering individuals to take proactive steps toward managing their health.

Recognizing the potential of genetic testing in revolutionizing healthcare, government launches several initiatives aimed at integrating genetic services into the public health infrastructure. One significant stride taken by National Cancer Institute that awarded USD 3.2 million grant to researchers at Georgetown University's Lombardi Comprehensive Cancer Center and the Rutgers Cancer Institute of New Jersey. This funding supports a five-year study enrolling 428 Black cancer patients who meet national guidelines for hereditary cancer testing into a randomized controlled trial and will evaluate the impact of these interventions on genetic education engagement, testing uptake, informed decision-making, and psychosocial outcomes. By addressing barriers to genetic testing and incorporating community input, the research aimed at improving access to screening, and medical management of cancers, ultimately advancing health equity in oncology care.

The market has been witnessing activity of the key players such as Myriad Genetics, Inc., Bio-Rad Laboratories, F. HOFFMANN-LA ROCHE LTD and Illumina, Inc. these players are actively engaged in seeking product approvals from USFDA to meet the need of global customers. For instance, in June 2024, Myriad Genetics, Inc, announced its ongoing innovations: MyChoice CDx HRD and BRACAnalysis CDx Germline Companion Diagnostic Tests for enhancing its product portfolio through research collaborations. Additionally, Myriad has initiated multiple research collaborations to investigate the potential of MRD in various cancers. Furthermore, developments in precision medicine online screening tools for cancer enable patient education for improved outcomes. For instance, in January 2025, Myriad Genetics, Inc, announced a study showing that patients were more likely to complete hereditary cancer testing when using an online screening tool combined with genetic education. This approach highlights the importance of digital tools and education in increasing engagement and participation in genetic testing for cancer risk assessment.

Thus, technological advancements in genetic testing, growing government initiatives and funding support and accelerated regulatory approvals are boosting the market growth for early detection and disease prevention.

Hereditary Cancer Testing Market Report Highlights:

• Based on cancer, breast cancer accounted for largest revenue share of 12.45% in 2024. The hereditary breast cancer testing market is expanding due to advancements in next-generation sequencing (NGS) and artificial intelligence (AI), enabling comprehensive risk assessments. Increased awareness, government initiatives, and expanded insurance coverage further drive adoption. These innovations facilitate early detection and personalized prevention strategies, enhancing patient outcomes.
• Based on technology, molecular testing dominated the market and accounted for the largest share of 56.36% in 2024.The molecular testing segment in the hereditary cancer testing market is expanding due to rising prevalence of cancer, advancements in next-generation and quick genetic analysis. These technologies enhance diagnostic accuracy and facilitate personalized treatment strategies. Additionally, increased awareness and insurance coverage are driving adoption.
• Based on test type, in 2024, predictive genetic testing emerged as the dominant segment in the hereditary cancer testing market, capturing 66.49% of the share. The increasing prevalence of genetic disorders and a growing emphasis on preventive healthcare further drive the adoption of predictive genetic tests.
• Based on end use, hospitals dominated the end-use segments with the largest market share of 55.11% in 2024 and were the fastest growing among the other segments over the period. Hospitals in collaboration with research universities are boosting the growth for this market.
• North America dominated the global market due to the presence of a large number of major market players, advancements in next-generation sequencing (NGS), increasing awareness of genetic risks, and expanded insurance coverage.
• Asia Pacific region is expected to witness fastest growth with a CAGR of 14.3% from 2025 to 2030, due to expansion by key players with innovative technologies coupled with accelerated diagnostic research capabilities.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Cancer
  • 1.2.2. Technology
  • 1.2.3. Regional scope
  • 1.2.4. Estimates and forecasts timeline.
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Cancer outlook
  • 2.2.2. Technology outlook
  • 2.2.3. Test Type outlook
  • 2.2.4. End Use outlook
  • 2.2.5. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Hereditary Cancer Testing Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Technological advancements of genetic testing in cancer detection
    • 3.2.1.2. Integration with precision medicine
    • 3.2.1.3. Growing awareness through public and government initiatives
    • 3.2.1.4. Rising prevalence of cancer
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High costs and limited insurance coverage
• 3.3. Hereditary Cancer Testing Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis

Chapter 4. Hereditary Cancer Testing Market: Cancer Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Hereditary Cancer Testing Market: Cancer Movement Analysis
• 4.3. Hereditary Cancer Testing Market Size & Trend Analysis, by cancer, 2018 to 2030 (USD Million)
• 4.4. Hereditary Cancer Testing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.5. Lung Cancer
  • 4.5.1. Lung Cancer Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Breast Cancer
  • 4.6.1. Breast Cancer Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Colorectal Cancer
  • 4.7.1. Colorectal Cancer Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.8. Cervical Cancer
  • 4.8.1. Cervical Cancer Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.9. Ovarian Cancer
  • 4.9.1. Ovarian Cancer Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.10. Prostate Cancer
  • 4.10.1. Prostate Cancer Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.11. Stomach/Gastric Cancer
  • 4.11.1. Stomach/Gastric Cancer Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.12. Melanoma
  • 4.12.1. Melanoma Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.13. Sarcoma
  • 4.13.1. Sarcoma Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.14. Uterine Cancer
  • 4.14.1. Uterine Cancer Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.15. Pancreatic Cancer
  • 4.15.1. Pancreatic Cancer Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.16. Others
  • 4.16.1. Others Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Hereditary Cancer Testing Market: Technology Estimates & Trend Analysis

• 5.1. Technology Market Share, 2024 & 2030
• 5.2. Segment Dashboard
• 5.3. Global Hereditary Cancer Testing Market by Technology Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 5.5. Cytogenetic
  • 5.5.1. Cytogenetic Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Biochemical
  • 5.6.1. Biochemical Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. Molecular Testing
  • 5.7.1. Molecular Testing Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Test type Market: Test Type Estimates & Trend Analysis

• 6.1. Test type Market Share, 2024 & 2030
• 6.2. Segment Dashboard
• 6.3. Global Test type Market by Capacity Outlook
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 6.5. Predictive Testing
  • 6.5.1. Predictive Testing Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Diagnostic Testing
  • 6.6.1. Diagnostic Testing Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. End Use Market: End Use Estimates & Trend Analysis

• 7.1. End Use Market Share, 2024 & 2030
• 7.2. Segment Dashboard
• 7.3. Global End Use Market by End Use Outlook
• 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 7.5. Diagnostic Centers
  • 7.5.1. Diagnostic Centers Market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Hospitals
  • 7.6.1. Hospitals Market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. Clinics
  • 7.7.1. Clinics Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Hereditary Cancer Testing Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2024 & 2030
• 8.2. Regional Market Dashboard
• 8.3. Global Regional Market Snapshot
• 8.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 8.5. North America
  • 8.5.1. North America: SWOT Analysis
  • 8.5.2. U.S.
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework/Reimbursement
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.3. Canada
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework/Reimbursement
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.4. Mexico
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Regulatory framework/Reimbursement
    • 8.5.4.3. Competitive scenario
    • 8.5.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 8.6. Europe
  • 8.6.1. Europe: SWOT Analysis
  • 8.6.2. UK
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework/Reimbursement
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.3. Germany
    • 8.6.3.1. Key country dynamics
    • 8.6.3.2. Regulatory framework/Reimbursement
    • 8.6.3.3. Competitive scenario
    • 8.6.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.4. France
    • 8.6.4.1. Key country dynamics
    • 8.6.4.2. Regulatory framework/Reimbursement
    • 8.6.4.3. Competitive scenario
    • 8.6.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.5. Italy
    • 8.6.5.1. Key country dynamics
    • 8.6.5.2. Regulatory framework/Reimbursement
    • 8.6.5.3. Competitive scenario
    • 8.6.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.6. Spain
    • 8.6.6.1. Key country dynamics
    • 8.6.6.2. Regulatory framework/Reimbursement
    • 8.6.6.3. Competitive scenario
    • 8.6.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.7. Norway
    • 8.6.7.1. Key country dynamics
    • 8.6.7.2. Regulatory framework/Reimbursement
    • 8.6.7.3. Competitive scenario
    • 8.6.7.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.8. Sweden
    • 8.6.8.1. Key country dynamics
    • 8.6.8.2. Regulatory framework/Reimbursement
    • 8.6.8.3. Competitive scenario
    • 8.6.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.9. Denmark
    • 8.6.9.1. Key country dynamics
    • 8.6.9.2. Regulatory framework/Reimbursement
    • 8.6.9.3. Competitive scenario
    • 8.6.9.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 8.7. Asia Pacific
  • 8.7.1. Asia Pacific: SWOT Analysis
  • 8.7.2. Japan
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework/Reimbursement
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.3. China
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework/Reimbursement
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.4. India
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory framework/Reimbursement
    • 8.7.4.3. Competitive scenario
    • 8.7.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.5. Australia
    • 8.7.5.1. Key country dynamics
    • 8.7.5.2. Regulatory framework/Reimbursement
    • 8.7.5.3. Competitive scenario
    • 8.7.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.6. South Korea
    • 8.7.6.1. Key country dynamics
    • 8.7.6.2. Regulatory framework/Reimbursement
    • 8.7.6.3. Competitive scenario
    • 8.7.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.7. Thailand
    • 8.7.7.1. Key country dynamics
    • 8.7.7.2. Regulatory framework/Reimbursement
    • 8.7.7.3. Competitive scenario
    • 8.7.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 8.8. Latin America
  • 8.8.1. Latin America: SWOT Analysis
  • 8.8.2. Brazil
    • 8.8.2.1. Key country dynamics
    • 8.8.2.2. Regulatory framework/Reimbursement
    • 8.8.2.3. Competitive scenario
    • 8.8.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8.3. Argentina
    • 8.8.3.1. Key country dynamics
    • 8.8.3.2. Regulatory framework/Reimbursement
    • 8.8.3.3. Competitive scenario
    • 8.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 8.9. MEA
  • 8.9.1. MEA: SWOT Analysis
  • 8.9.2. South Africa
    • 8.9.2.1. Key country dynamics
    • 8.9.2.2. Regulatory framework/Reimbursement
    • 8.9.2.3. Competitive scenario
    • 8.9.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9.3. Saudi Arabia
    • 8.9.3.1. Key country dynamics
    • 8.9.3.2. Regulatory framework/Reimbursement
    • 8.9.3.3. Competitive scenario
    • 8.9.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9.4. UAE
    • 8.9.4.1. Key country dynamics
    • 8.9.4.2. Regulatory framework/Reimbursement
    • 8.9.4.3. Competitive scenario
    • 8.9.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9.5. Kuwait
    • 8.9.5.1. Key country dynamics
    • 8.9.5.2. Regulatory framework
    • 8.9.5.3. Competitive scenario
    • 8.9.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Recent Developments & Impact Analysis, By Key Market Participants
• 9.2. Company/Competition Categorization
• 9.3. Vendor Landscape
  • 9.3.1. List of key distributors and channel partners
  • 9.3.2. Key customers
  • 9.3.3. Key company market share analysis, 2024
  • 9.3.4. Myriad Genetics, Inc.
    • 9.3.4.1. Company overview
    • 9.3.4.2. Financial performance
    • 9.3.4.3. Services benchmarking
    • 9.3.4.4. Strategic initiatives
  • 9.3.5. Invitae Corporation
    • 9.3.5.1. Company overview
    • 9.3.5.2. Financial performance
    • 9.3.5.3. Services benchmarking
    • 9.3.5.4. Strategic initiatives
  • 9.3.6. Bio-Rad Laboratories
    • 9.3.6.1. Company overview
    • 9.3.6.2. Financial performance
    • 9.3.6.3. Services benchmarking
    • 9.3.6.4. Strategic initiatives
  • 9.3.7. CSL Ltd
    • 9.3.7.1. Company overview
    • 9.3.7.2. Financial performance
    • 9.3.7.3. Services benchmarking
    • 9.3.7.4. Strategic initiatives
  • 9.3.8. Qiagen NV
    • 9.3.8.1. Company overview
    • 9.3.8.2. Financial performance
    • 9.3.8.3. Services benchmarking
    • 9.3.8.4. Strategic initiatives
  • 9.3.9. Danaher Corporation
    • 9.3.9.1. Company overview
    • 9.3.9.2. Financial performance
    • 9.3.9.3. Services benchmarking
    • 9.3.9.4. Strategic initiatives
  • 9.3.10. Thermo Fisher Scientific
    • 9.3.10.1. Company overview
    • 9.3.10.2. Financial performance
    • 9.3.10.3. Services benchmarking
    • 9.3.10.4. Strategic initiatives
  • 9.3.11. Abbott Laboratories
    • 9.3.11.1. Company overview
    • 9.3.11.2. Financial performance
    • 9.3.11.3. Services benchmarking
    • 9.3.11.4. Strategic initiatives
  • 9.3.12. EUROFINS SCIENTIFIC
    • 9.3.12.1. Company overview
    • 9.3.12.2. Financial performance
    • 9.3.12.3. Services benchmarking
    • 9.3.12.4. Strategic initiatives
  • 9.3.13. F. HOFFMANN-LA ROCHE LTD
    • 9.3.13.1. Company overview
    • 9.3.13.2. Financial performance
    • 9.3.13.3. Services benchmarking
    • 9.3.13.4. Strategic initiatives
  • 9.3.14. Illumina, Inc.
    • 9.3.14.1. Company overview
    • 9.3.14.2. Financial performance
    • 9.3.14.3. Services benchmarking
    • 9.3.14.4. Strategic initiatives